Supplemental material
OncoImmunology
Volume 13, 2024 - Issue 1
Open access
386
Views
0
CrossRef citations to date
0
Altmetric
Original Research
Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism
Iñaki Eguren-Santamaríaa Combination Strategies for Translational Immunotherapy, Immunology and Immunotherapy Program, Centro de Investigación Médica Aplicada (CIMA) Universidad de Navarra, Pamplona, Spain;b Medical Oncology Department, Clínica Universidad de Navarra, Pamplona, Spain;c Immunology, Navarra Institute for Health Research (IdiSNA), Pamplona, SpainView further author information
, Inmaculada Rodrígueza Combination Strategies for Translational Immunotherapy, Immunology and Immunotherapy Program, Centro de Investigación Médica Aplicada (CIMA) Universidad de Navarra, Pamplona, Spain;c Immunology, Navarra Institute for Health Research (IdiSNA), Pamplona, SpainView further author information
, Claudia Herrero-Martina Combination Strategies for Translational Immunotherapy, Immunology and Immunotherapy Program, Centro de Investigación Médica Aplicada (CIMA) Universidad de Navarra, Pamplona, Spain;c Immunology, Navarra Institute for Health Research (IdiSNA), Pamplona, SpainView further author information
, Eva Fernández de Piérolaa Combination Strategies for Translational Immunotherapy, Immunology and Immunotherapy Program, Centro de Investigación Médica Aplicada (CIMA) Universidad de Navarra, Pamplona, Spain;c Immunology, Navarra Institute for Health Research (IdiSNA), Pamplona, SpainView further author information
, Arantza Azpilikuetaa Combination Strategies for Translational Immunotherapy, Immunology and Immunotherapy Program, Centro de Investigación Médica Aplicada (CIMA) Universidad de Navarra, Pamplona, Spain;c Immunology, Navarra Institute for Health Research (IdiSNA), Pamplona, SpainView further author information
, Sandra Sánchez-Gregorioa Combination Strategies for Translational Immunotherapy, Immunology and Immunotherapy Program, Centro de Investigación Médica Aplicada (CIMA) Universidad de Navarra, Pamplona, Spain;c Immunology, Navarra Institute for Health Research (IdiSNA), Pamplona, SpainView further author information
, Elixabet Bolañosa Combination Strategies for Translational Immunotherapy, Immunology and Immunotherapy Program, Centro de Investigación Médica Aplicada (CIMA) Universidad de Navarra, Pamplona, Spain;c Immunology, Navarra Institute for Health Research (IdiSNA), Pamplona, SpainView further author information
, Gabriel Gomisa Combination Strategies for Translational Immunotherapy, Immunology and Immunotherapy Program, Centro de Investigación Médica Aplicada (CIMA) Universidad de Navarra, Pamplona, Spain;c Immunology, Navarra Institute for Health Research (IdiSNA), Pamplona, SpainView further author information
, Paula Molero-Gleza Combination Strategies for Translational Immunotherapy, Immunology and Immunotherapy Program, Centro de Investigación Médica Aplicada (CIMA) Universidad de Navarra, Pamplona, Spain;c Immunology, Navarra Institute for Health Research (IdiSNA), Pamplona, SpainView further author information
, Enrique Chacónd Gynecology & Obstetrics Department, Clínica Universidad de Navarra, Pamplona, SpainView further author information
, José Ángel Mínguezd Gynecology & Obstetrics Department, Clínica Universidad de Navarra, Pamplona, SpainView further author information
, Santiago Chivae Urology Department, Clínica Universidad de Navarra, Pamplona, SpainView further author information
, Fernando Diez-Caballeroe Urology Department, Clínica Universidad de Navarra, Pamplona, SpainView further author information
, Carlos de Andreac Immunology, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain;f Pathology Department, Clínica Universidad de Navarra, Pamplona, SpainView further author information
, Álvaro Teijeiraa Combination Strategies for Translational Immunotherapy, Immunology and Immunotherapy Program, Centro de Investigación Médica Aplicada (CIMA) Universidad de Navarra, Pamplona, Spain;c Immunology, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain;g Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, SpainView further author information
, Miguel F. Sanmameda Combination Strategies for Translational Immunotherapy, Immunology and Immunotherapy Program, Centro de Investigación Médica Aplicada (CIMA) Universidad de Navarra, Pamplona, Spain;b Medical Oncology Department, Clínica Universidad de Navarra, Pamplona, Spain;c Immunology, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain;g Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, SpainCorrespondence[email protected]
View further author information
& View further author information
Ignacio Meleroc Immunology, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain;g Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain;h Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain;i Nuffield Department of Medicine, University of Oxford, Oxford, UKCorrespondence[email protected]
https://orcid.org/0000-0002-1360-348XView further author information
Article: 2373519
|
Received 18 Mar 2024, Accepted 24 Jun 2024, Published online: 09 Jul 2024
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.